EBRO 2017

How to combine… chemotherapy and RT

Study

Type of study

n. pts Inclusion criteria

RT (Gy)

Type of CT Main Results

SWOG 9024

Phase II 30

T3 +, N0 45 + 25.2 Daily 5-FU 13/30: PSA < 1.0 ng/dL 6/13 negative post- treatment biopsy

Khil et al Phase II 65

cT2b-c + GS 9-10, cT3, or cTxN1M0 High risk and/or N+

45 + 20-25 Estramustine Phosphate + Vinblastine

undetectable PSA at nadir: 86% biochemical remission: 48%

MSKCC Phase II 27

75.6

Estramustine Phosphate + Vinblastine

5-y BRFS: 34%

Acute G3 GI tox: 35% Acute G3 GI tox: 48%

Khil et al Phase II 50

IR-HR 70.2

Docetaxel

Median FUP 54 m 5-y bRFS = 66% 5-y OS = 92%